medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-16-42-45medsovet-404Research ArticleБронхиальная астмаBronchial asthmaФенотипирование астмы и альтернативы в терапииAsthma phenotyping and alternative therapyНазароваЕ. В.NazarovaE. V.noemail@neicon.ruГосударственный научный центр «Институт иммунологии» Федерального медико-биологического агентства, МоскваРоссияResearch Center Institute of Immunology of the Federal Medical and Biological Agency, MoscowRussian Federation2015301220150164245Copyright © Назарова Е.В., 20152015Назарова Е.В.Nazarova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/404

По данным ВОЗ, астма является сегодня одним из самых распространенных заболеваний в мире, охватив свыше 300 млн человек, и ее распространенность продолжает расти, особенно в развивающихся странах. Астма является сложным заболеванием, которое включает множество вариантов течения. В настоящее время очень большой интерес и дискуссию вызывает фенотипирование астмы.

According to the WHO, asthma is now one of the most common diseases in the world affecting more than 300 million people, and its incidence continues to grow, especially in developing countries. Asthma is a complex disease with a variety of course patterns. Currently, phenotyping of asthma is a matter of great interest and debate.

бронхиальная астмафенотипированиеингаляционные глюкокортикостероидыдлительно действующие в2-агонистыasthmaphenotypinginhaled corticosteroidslong-acting β2-agonistsReferencesWalker C et aL. Allergic and nonallelic asthmatics have distinct patterns of T-ceLL activation and cytokine production in peripheral blood and bronchoaLveoLar lavage. Am Rev Respir Dis. 1992, 146: 109-115.Walker C et aL. Allergic and nonallelic asthmatics have distinct patterns of T-ceLL activation and cytokine production in peripheral blood and bronchoaLveoLar lavage. Am Rev Respir Dis. 1992, 146: 109-115.WaLker C et aL. T ceLL subsets and their soluble products regulate eosinophiLia in aLLergic and non-aLLergic asthma. J Immunol. 1991, 146: 1829-1835.WaLker C et aL. T ceLL subsets and their soluble products regulate eosinophiLia in aLLergic and non-aLLergic asthma. J Immunol. 1991, 146: 1829-1835.Duan OL et aL. ReguLatory hapLotypes in ARGI are associated with aLtered bronchodiLator response. Am J Respir Crit Care Med. 2011, 183: 449-454.Duan OL et aL. ReguLatory hapLotypes in ARGI are associated with aLtered bronchodiLator response. Am J Respir Crit Care Med. 2011, 183: 449-454.Virchow JC et aL. T ceLLs and cytokines in bronchoaLveoLar Lavage fLuid after segmentaL aLLergen provocation in atopic asthma. Am J Respir Crit Care Med. 1995, 151: 960-968.Virchow JC et aL. T ceLLs and cytokines in bronchoaLveoLar Lavage fLuid after segmentaL aLLergen provocation in atopic asthma. Am J Respir Crit Care Med. 1995, 151: 960-968.Knudsen TB et aL. A popuLation-based cLinicaL study of aLLergic and non-aLLergic asthma. J.Asthma, 2009, 46: 91-94.Knudsen TB et aL. A popuLation-based cLinicaL study of aLLergic and non-aLLergic asthma. J.Asthma, 2009, 46: 91-94.Gibson PG. InfLammatory phenotypes in aduLt asthma: cLinicaL appLications. Clin Respir J, 2009, 3: 198-206.Gibson PG. InfLammatory phenotypes in aduLt asthma: cLinicaL appLications. Clin Respir J, 2009, 3: 198-206.Chiesi Pharmaceutici SpA. ModuLite®: the vaLue of Chiesi_s technoLgy in the treatment of asthma and COPD (onLine). AvaiLabLe from URL: hppt//www.chiesigroup.com (Accessed 2006 May 25).Chiesi Pharmaceutici SpA. ModuLite®: the vaLue of Chiesi_s technoLgy in the treatment of asthma and COPD (onLine). AvaiLabLe from URL: hppt//www.chiesigroup.com (Accessed 2006 May 25).Thongngarm T, SiLkoff PE, Kossack WS, NeLson HS. HydrofLuoroaLkane 134A becLomethasone or chLorofLuorocarbon fLuticasone: effect on smaLL airways in poorLy controLLed asthma. J.Asthma, 2005, 42: 257-263.Thongngarm T, SiLkoff PE, Kossack WS, NeLson HS. HydrofLuoroaLkane 134A becLomethasone or chLorofLuorocarbon fLuticasone: effect on smaLL airways in poorLy controLLed asthma. J.Asthma, 2005, 42: 257-263.GoLdin JG, Tashkin DP, KLeerup EC et aL. Comparative effects of hydrofLuoroaLkane and chLorofLuorocarbon becLometha-sone dipropionate inhaLation on smaLL airways: assessment with functionaL heLicaL thin section computed tomography. J. Allergy Clin. Immunol. 1999, 104: 258-267.GoLdin JG, Tashkin DP, KLeerup EC et aL. Comparative effects of hydrofLuoroaLkane and chLorofLuorocarbon becLometha-sone dipropionate inhaLation on smaLL airways: assessment with functionaL heLicaL thin section computed tomography. J. Allergy Clin. Immunol. 1999, 104: 258-267.Ohbayashi H. One year evaLuation of the preventative effect of hydrofLuoroaLkane becLomethasone dipropionate on eosinophiLic infLammation of asthmatic peripheraL airways. Respiration 2007, 74: 146-153.Ohbayashi H. One year evaLuation of the preventative effect of hydrofLuoroaLkane becLomethasone dipropionate on eosinophiLic infLammation of asthmatic peripheraL airways. Respiration 2007, 74: 146-153.Van Schayck CP, DonneLL D. The efficacy and safety of OVAR (hydrofLuoroaLkane becLometasone diproprionate extrafine aerosoL) in asthma (part 1): an update of cLinicaL experience in aduLts. Int. J. Clin. Pract. 2004, 58: 678-688.Van Schayck CP, DonneLL D. The efficacy and safety of OVAR (hydrofLuoroaLkane becLometasone diproprionate extrafine aerosoL) in asthma (part 1): an update of cLinicaL experience in aduLts. Int. J. Clin. Pract. 2004, 58: 678-688.Bonnet Gonod F, Kottakis I, BaLLabio M et aL. Superior efficacy of a Low daiLy dose of a new fixed combination of becLometasone dipropionate/formoteroL pMDI compared to an increased daiLy dose of BDP in moderate persistent asthma: a 3 month cLinicaL study. 16th Annual Congress of the European Respiratory Society, 2006, Sep. 2-6, Munich: 1237.Bonnet Gonod F, Kottakis I, BaLLabio M et aL. Superior efficacy of a Low daiLy dose of a new fixed combination of becLometasone dipropionate/formoteroL pMDI compared to an increased daiLy dose of BDP in moderate persistent asthma: a 3 month cLinicaL study. 16th Annual Congress of the European Respiratory Society, 2006, Sep. 2-6, Munich: 1237.Huchon G, Magnussen H, ChuchaLin A et aL. Lung function and asthma controL with becLomethasone and formoteroL in a singLe inhaLer. Respir. Med. 2009, 103: 41-49.Huchon G, Magnussen H, ChuchaLin A et aL. Lung function and asthma controL with becLomethasone and formoteroL in a singLe inhaLer. Respir. Med. 2009, 103: 41-49.

The authors declare that there are no conflicts of interest present.